Try our Advanced Search for more refined results

IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION

Track this case

Case overview

Case Number:

2:16-md-02724

Court:

Pennsylvania Eastern

Nature of Suit:

Other Statutes: Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

CYNTHIA M. RUFE

Firms

Companies

Government Agencies

Sectors & Industries:

  1. July 14, 2020

    States' Case To Be Bellwether In Generic Drug Price-Fix MDL

    The Pennsylvania federal judge overseeing multidistrict litigation for price-fixing allegations in the generic drug industry has selected a case from state attorneys general to serve as a bellwether along with three private cases centered on individual drugs.

  2. June 10, 2020

    AGs Pile On Generics Cos. With 3rd Price-Fixing Complaint

    State enforcers added more treatments to their price-fixing case against generic-drug makers with a third complaint Wednesday in Connecticut federal court accusing 26 companies and 10 individuals of "rampant" collusion on topically applied treatments.

  3. April 03, 2020

    States' Suit Touted For Bellwether In Generics Price-Fix Case

    Buyers accusing generic-drug makers of price-fixing urged a Pennsylvania federal judge Thursday to accept a special master's recommendation and pick a lawsuit by states as their bellwether conspiracy case, pushing back against Teva Pharmaceuticals' objection to the special master's choice.

  4. March 13, 2020

    States' Case No Bellwether In Price-Fixing MDL, Teva Says

    Teva Pharmaceuticals and other generic-drug makers slammed a special master's recommendation that an antitrust suit by multiple states and territories be the bellwether in Pennsylvania-based multidistrict litigation, arguing it gives an unfair edge to previously filed class actions lodging the same price-fixing claims.

  5. February 28, 2020

    Justices Partially Stay Generic Drug Price-Fixing Discovery

    The U.S. Supreme Court hit the brakes Friday on an expansive part of the discovery order in the massive multidistrict litigation from state attorneys general and private plaintiffs accusing dozens of generic-drug companies of an industrywide price-fixing conspiracy.

  6. February 21, 2020

    Teva Floated As Bellwether In Generic Drug Price-Fixing MDL

    A case brought by 44 state attorneys general against Teva Pharmaceuticals and several other drugmakers should be the bellwether for a massive multidistrict litigation over alleged conspiracies to fix the prices of generic drugs, according to a special master's report Thursday.

  7. February 18, 2020

    Former Teva Exec Calls AGs' Price-Fixing Claims 'Threadbare'

    A former Teva executive has urged a Pennsylvania federal judge to toss price-fixing accusations against her from a coalition of 44 state attorneys general as part of multidistrict litigation alleging industrywide price-fixing by generic-drug makers, blasting the claims as "threadbare."

  8. January 29, 2020

    State AGs Diss Pfizer's Effort To Flee Price-Fixing MDL

    A coalition of state attorneys general is bashing Pfizer's attempt to exit multidistrict litigation alleging industrywide price-fixing by generic-drug makers, asserting that Pfizer must be held accountable for its generic-drug subsidiary's alleged involvement in the scheme because the companies are "one and the same."

  9. January 10, 2020

    'Polite F-U' Email Stays In States' Drug Price-Fixing Case

    A Pennsylvania federal judge refused Heritage Pharmaceuticals Inc.'s bid to seal an email about an industry group's planned "polite f-u" response to a congressional inquiry into generic-drug price-fixing claims, ruling Thursday that the email isn't subject to attorney-client privilege.

  10. December 02, 2019

    Pfizer Claims No Link To Generic-Drug Price-Fix Plot

    Pfizer Inc. is seeking to exit the sweeping Pennsylvania multidistrict litigation alleging it conspired with other major drugmakers to keep generic prices high, as the branded drugmaker said its only ties to the allegations stem from a subsidiary, and that's not enough.